Powered by

Masimo Announces CE Marking of Pediatric Indication for Next Generation SedLine® Brain Function Monitoring

Mar 04, 2019 - Business Wire

Masimo  (NASDAQ: MASI) announced today the CE marking of Next Generation SedLine® brain function monitoring for pediatric patients (1-18 years of age). With this clearance, the benefits of Next Generation SedLine are available for all patients one year old and above in CE mark countries. SedLine helps clinicians monitor the state of the brain under anesthesia with bilateral data acquisition and processing of four leads of electroencephalogram (EEG) signals.

This press release features mu...